Radiotherapy in Breast Cancer

Hasan, Mohammad Mehedi; Mohanan, Parvathy; Bibi, Shabana; Babu, Catherine; Roy, Yohan Joe; Mathews, Ashlyn; Khatri, Govinda; Papadakos, Stavros P.

doi:10.1007/16833_2023_176

Cited by 2 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Radiation therapy is given after lumpectomy to destroy any remaining cancer cells and reduce the risk of recurrence. External beam radiation is directed at the breast or chest wall [12,13]. • Hormonal therapy is used for hormonally-responsive cancers like ER + or PR+, for example, tamoxifen and aromatase inhibitors (e.g., anastrozole, letrozole, exemestane).…”

Section: Introductionmentioning

confidence: 99%

MiRNAs as Promising Therapeutic Targets for Breast Cancer

Fakhry,

Abdel-Hamed,

Mesbah

et al. 2024

OBM Genet

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cause of cancer-related death and is the malignancy most frequently diagnosed in females worldwide. BC incidence is predicted to continue increasing worldwide. Without interventions, annual new cases will reach over 3 million by 2030. Genetic abnormalities account for almost 70% of all BC cases worldwide. Biological pathways implicated include non-coding RNAs (ncRNAs). MiRNAs are small non-coding RNA molecules that play a role in post-transcriptional regulation of gene expression. They can function as either tumor suppressors or oncogenes, and their role depends on the specific miRNA and target genes affected. The research on miRNA-based cancer treatments has yielded promising results. Depending on recent data, the goal of this review was to summarize the mechanisms that explain the role of some miRNAs in BC pathogenesis and drug resistance. However, highlighting the areas needing further exploration and more research is required before using microRNAs in clinical settings.

show abstract

Section: Introductionmentioning

confidence: 99%